Aims: We investigated whether radiation-induced nontargeted effects are involved in the cytotoxic effects of anticell surface monoclonal antibodies labeled with Auger electron emitters, such as iodine 125 (monoclonal antibodies labeled with 125I [125I-mAbs]). Results: We showed that the cytotoxicity of 125I-mAbs targeting the cell membrane of p53+/+ HCT116 colon cancer cells is mainly due to nontargeted effects. Targeted and nontargeted cytotoxicities were inhibited in vitro following lipid raft disruption with Methyl-β-cyclodextrin (MBCD) or filipin or use of radical oxygen species scavengers. 125I-mAb efficacy was associated with acid sphingomyelinase activation and modulated through activation of the AKT, extracellular signal-related kinase ½ (ERK1/2), p38 kinase, c-Jun N-terminal kinase (JNK) signaling pathways, and also of phospholipase C-γ (PLC-γ), proline-rich tyrosine kinase 2 (PYK-2), and paxillin, involved in Ca2+ fluxes. Moreover, the nontargeted response induced by directing 5-[(125)I]iodo-2′-deoxyuridine to the nucleus was comparable to that of 125I-mAb against cell surface receptors. In vivo, we found that the statistical significance of tumor growth delay induced by 125I-mAb was removed after MBCD treatment and observed oxidative DNA damage beyond the expected Auger electron range. These results suggest the involvement of nontargeted effects in vivo also. Innovation: Low-energy Auger electrons, such as those emitted by 125I, have a short tissue range and are usually targeted to the nucleus to maximize their cytotoxicity. In this study, we show that targeting the cancer cell surface with 125I-mAbs produces a lipid raft-mediated nontargeted response that compensates for the inferior efficacy of non-nuclear targeting. Conclusion: Our findings describe the mechanisms involved in the efficacy of 125I-mAbs targeting the cancer cell surface. Antioxid. Redox Signal. 25, 467–484.
Get full access to this article
View all access options for this article.
References
1.
AnthonyLB, et al.Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med, 32: 123–132, 2002.
2.
AzzamEI, de ToledoSM, and LittleJB. Oxidative metabolism, gap junctions and the ionizing radiation-induced bystander effect. Oncogene, 22: 7050–7057, 2003.
3.
AzzamEI, et al.Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particle-irradiated normal human fibroblast cultures. Cancer Res, 62: 5436–5442, 2002.
4.
BelyakovOV, et al.Delayed lethality, apoptosis and micronucleus formation in human fibroblasts irradiated with X-rays or alpha-particles. Int J Radiat Biol, 75: 985–993, 1999.
5.
BishayeeA, RaoDV, and HowellRW. Evidence for pronounced bystander effects caused by nonuniform distributions of radioactivity using a novel three-dimensional tissue culture model. Radiat Res, 152: 88–97, 1999.
6.
BoydM, et al.Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med, 47: 1007–1015, 2006.
7.
BradleyEW, ChanPC, and AdelsteinSJ. The radiotoxicity of iodine-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA. Radiat Res, 64: 555–563, 1975.
8.
ChalfantCE, et al.Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem, 274: 20313–20317, 1999.
9.
ChenP, et al.Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med, 44: 1469–1478, 2003.
10.
ChouinN, et al.Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat Res, 171: 664–673, 2009.
11.
ChurchLD, et al.TNFR1-induced sphingomyelinase activation modulates TCR signaling by impairing store-operated Ca2+ influx. J Leukoc Biol, 78: 266–278, 2005.
12.
CommerfordSL, et al.Radiotoxicity of intranuclear 125I atoms not bound to DNA. Int J Radiat Biol Relat Stud Phys Chem Med, 37: 547–554, 1980.
13.
CordesN, et al.Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene, 26: 6851–6862, 2007.
14.
CostantiniDL, et al.111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med, 48: 1357–1368, 2007.
15.
CostantiniDL, et al.Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med, 51: 1084–1091, 2010.
16.
DelpassandES, et al.Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm, 23: 292–300, 2008.
17.
DeSombreER, et al.Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger electron-emitting estrogens—Theoretical and practical considerations. Acta Oncol, 39: 659–666, 2000.
18.
GalanisE, et al.Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol, 12: 701–707, 2001.
19.
HamadaN. Evidence and significance of non-targeted effects of ionizing radiation. Curr Mol Pharmacol, 4: 78, 2011.
20.
HavakiS, et al.The role of oxidative DNA damage in radiation induced bystander effect. Cancer Lett, 356: 43–51, 2015.
21.
HehlgansS, EkeI, and CordesN. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Int J Radiat Oncol Biol Phys, 83: e669–e676, 2012.
22.
HoferKG and HughesWL. Radiotoxicity of intranuclear tritium, 125 iodine and 131 iodine. Radiat Res, 47: 94–101, 1971.
23.
HummJL, HowellRW, and RaoDV. Dosimetry of Auger-electron-emitting radionuclides: Report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys, 21: 1901–1915, 1994.
24.
ICRP, A.o.t. (Ed). The 2007 Recommendations of the International Commission on Radiological Protection. Oxford: Elsevier, Vol. 37, 2007.
25.
KassisAI. Radiotargeting agents for cancer therapy. Expert Opin Drug Deliv, 2: 981–991, 2005.
26.
KassisAI, et al.Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res, 90: 362–373, 1982.
27.
KassisAI, et al.Radiotoxicity of an 125I-labeled DNA intercalator in mammalian cells. Radiat Res, 118: 283–294, 1989.
28.
KassisAI, et al.Radiotoxicity of 125I in mammalian cells. Radiat Res, 111: 305–318, 1987.
29.
KassisAI, SastryKS, and AdelsteinSJ. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: Implications of localized energy deposition by Auger processes. Radiat Res, 109: 78–89, 1987.
30.
KohlerG, HoweSC, and MilsteinC. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol, 6: 292–295, 1976.
31.
KrenningEP, et al.The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res, 153: 1–13, 2000.
32.
LajoieP, et al.Caveolin-1 regulation of dynamin-dependent, raft-mediated endocytosis of cholera toxin-B sub-unit occurs independently of caveolae. J Cell Mol Med, 13: 3218–3225, 2009.
33.
LehnertBE, GoodwinEH, and DeshpandeA. Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res, 57: 2164–2171, 1997.
34.
LevS, et al.Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature, 376: 737–745, 1995.
35.
LiL, et al.A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg, 113: 192–198, 2010.
36.
LiPL and GulbinsE. Lipid rafts and redox signaling. Antioxid Redox Signal, 9: 1411–1415, 2007.
37.
LimourisGS, et al.Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging, 35: 1827–1837, 2008.
38.
LyngFM, et al.The involvement of calcium and MAP kinase signaling pathways in the production of radiation-induced bystander effects. Radiat Res, 165: 400–409, 2006.
39.
LyngFM, SeymourCB, and MothersillC. Initiation of apoptosis in cells exposed to medium from the progeny of irradiated cells: A possible mechanism for bystander-induced genomic instability?. Radiat Res, 157: 365–370, 2002.
40.
MacapinlacHA, et al.Pilot clinical trial of 5-[125I]iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med, 37: 25S–29S, 1996.
41.
MarianiG, et al.Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med, 34: 1175–1183, 1993.
42.
MothersillC and SeymourCB. Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium. Radiat Res, 149: 256–262, 1998.
43.
NagasawaH, et al.Involvement of membrane signaling in the bystander effect in irradiated cells. Cancer Res, 62: 2531–2534, 2002.
44.
NarayananPK, GoodwinEH, and LehnertBE. Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res, 57: 3963–3971, 1997.
45.
OskouianB and SabaJD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol, 688: 185–205, 2010.
46.
PaillasS, et al.Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol, 40: 471–480, 2013.
47.
PatelHH, MurrayF, and InselPA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol, 48: 359–391, 2008.
48.
PironB, et al.DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy. Nucl Med Biol, 41Suppl: e75–e83, 2014.
49.
PomplunE, BoozJ, and CharltonDE. A Monte Carlo simulation of Auger cascades. Radiat Res, 111: 533–552, 1987.
50.
PougetJP, et al.Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res, 170: 192–200, 2008.
51.
PriseKM and O'SullivanJM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer, 9: 351–360, 2009.
52.
QuangTS and BradyLW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys, 58: 972–975, 2004.
53.
SantoroL, et al.Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med, 50: 2033–2041, 2009.
54.
SastryKS and RaoDV. Dosimetry of low energy electrons. In: Physics of Nuclear Medicine: Recent Advances, edited by RaoDV, ChandraR, and GrahamMC. New York: American Institute of Physics, 1984, pp. 169–208.
55.
SawantSG, et al.The bystander effect in radiation oncogenesis: I. Transformation in C3H 10T1/2 cells in vitro can be initiated in the unirradiated neighbors of irradiated cells. Radiat Res, 155: 397–401, 2001.
56.
Scheel-ToellnerD, et al.Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood, 104: 2557–2564, 2004.
57.
SingerSJ, and NicolsonGL. The fluid mosaic model of the structure of cell membranes. Science, 175: 720–731, 1972.
58.
SissonJC, et al.Treatment of neuroblastoma with [125I]metaiodobenzylguanidine. J Nucl Biol Med, 35: 255–259, 1991.
59.
SmithEL and SchuchmanEH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J, 22: 3419–3431, 2008.
60.
ToddDG, et al.Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells. J Recept Signal Transduct Res, 19: 885–908, 1999.
61.
ValerieK, et al.Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther, 6: 789–801, 2007.
62.
VallisKA, et al.Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. Am J Nucl Med Mol Imaging, 4: 181–192, 2014.
63.
WalickaMA, AdelsteinSJ, and KassisAI. Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: clonogenic survival. Radiat Res, 149: 142–146, 1998.
64.
WalickaMA, AdelsteinSJ, and KassisAI. Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: double-strand breaks. Radiat Res, 149: 134–141, 1998.
65.
WeltS, et al.Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol, 14: 1787–1797, 1996.
66.
XueLY, et al.Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A, 99: 13765–13770, 2002.
67.
ZhangAY, et al.Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. Antioxid Redox Signal, 9: 817–828, 2007.
68.
ZhangY, et al.Ceramide-enriched membrane domains—Structure and function. Biochim Biophys Acta, 1788: 178–183, 2009.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
